Teva Pharmaceutical Industries Ltd (TEVA) — Long-term Investment Intensity
Teva Pharmaceutical Industries Ltd (TEVA) has a Long-term Investment Intensity of 0.1% as of December 2018. Long-term investments of ILA61.00 Million represent 0.1% of total assets of ILA60.68 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Teva Pharmaceutical Industries Ltd (TEVA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Teva Pharmaceutical Industries Ltd Long-term Investment Intensity (2013–2018)
This chart shows how Teva Pharmaceutical Industries Ltd's Long-term Investment Intensity has evolved across 6 annual periods from 2013 to 2018. As of December 2018, the intensity stands at 0.1%, reflecting long-term investments of ILA61.00 Million against total assets of ILA60.68 Billion ILA. For the complete balance sheet picture, see Teva Pharmaceutical Industries Ltd asset portfolio.
Annual Long-term Investment Intensity for Teva Pharmaceutical Industries Ltd (2013–2018)
The table below presents the year-by-year Long-term Investment Intensity for Teva Pharmaceutical Industries Ltd from 2013 to 2018, covering 6 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read how much debt does Teva Pharmaceutical Industries Ltd carry for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (ILA) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2018 | 0.1% | ILA61.00 Million | ILA60.68 Billion | ▼ 0.0 pp |
| 2017 | 0.1% | ILA83.00 Million | ILA70.61 Billion | ▼ -0.2 pp |
| 2016 | 0.3% | ILA283.00 Million | ILA92.89 Billion | ▼ -2.4 pp |
| 2015 | 2.7% | ILA1.45 Billion | ILA54.26 Billion | ▲ +2.3 pp |
| 2014 | 0.4% | ILA176.00 Million | ILA46.42 Billion | ▲ +0.0 pp |
| 2013 | 0.4% | ILA179.00 Million | ILA47.51 Billion | — |